Research and Markets: 2013 Report on the International Non-Small Cell Lung Cancer Therapeutics Market: Forecast and Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/8xqphh/halaven) has announced the addition of the "2013 Report on the International Non-Small Cell Lung Cancer Therapeutics Market: Forecast and Analysis to 2022" report to their offering.

Halaven, or Non-Small Cell Lung Cancer (NSCLC), is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations.

Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Scope

• Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Halaven including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Halaven for the top nine countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.
  

Reasons to Buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Halaven performance
• Obtain sales forecast for Halaven from 2012-2022 in top nine countries

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Halaven (eribulin mesylate)

9 Appendix

For more information visit http://www.researchandmarkets.com/research/8xqphh/halaven

Research and Markets
Laura Wood, Senior Manager.
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Oncology